Brief: Krystal Biotech Receives FDA Approval For Vyjuvek
19/05/2023 19:01
May 19 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH RECEIVES FDA APPROVAL FOR THE FIRST-EVER
REDOSABLE GENE THERAPY, VYJUVEK™ (BEREMAGENE GEPERPAVEC-SVDT)
FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
* KRYSTAL BIOTECH INC - VYJUVEK IS EXPECTED TO BE AVAILABLE
IN
UNITED STATES IN Q3 OF 2023
* KRYSTAL BIOTECH INC - COMPANY WILL BEGIN PROMOTION OF
VYJUVEK
IMMEDIATELY
* KRYSTAL BIOTECH- IS WORKING WITH PHARMACEUTICALS AND
MEDICAL
DEVICES AGENCY IN JAPAN TO STUDY VYJUVEK AND SEEK APPROVAL FOR
POTENTIAL LAUNCH IN 2025
* KRYSTAL BIOTECH- EXPECTS STARTING OFFICIAL MARKETING
AUTHORIZATION APPLICATION PROCEDURE FOR VYJUVEK IN EUROPE IN H2
OF 2023
Source text for Eikon: ID:nGNX4Ls5qH
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion